Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress.
OBJECTIVE
Dihydromyricetin (DMY), a flavonoid component isolated from Ampelopsis grossedentata, was recently reported to ameliorate nonalcoholic fatty liver disease (NAFLD) in patients. However, the underlying mechanisms of this action remain unknown. Here, we evaluate the effect of DMY on an in vitro model of NAFLD and investigate the signal transduction pathways underlying DMY treatment.


METHODS
Oleic acid (OA) induced hepatic steatosis was established in L02 and HepG2 cells as in vitro model of NAFLD. Cell apoptosis, lipid accumulation and oxide stress were evaluated by flow cytometry, oil red O staining, and cellular biochemical assays, respectively. Signaling pathways involved in lipid metabolism including PPARγ, AMPK, and AKT were investigated by Western blot and RT-qPCR.


RESULTS
DMY protected cells against apoptosis and lipid accumulation induced by oleic acid. DMY decreased the levels of cellular triglycerides (TG), cholesterol (TC) and malondialdehyde (MDA), while at the same time increasing the level of superoxide dismutase (SOD). DMY suppressed the expression of PPARγ and the phosphorylation of AKT, and promoted the phosphorylation of AMPK.


CONCLUSIONS
Our study suggests that DMY ameliorates OA-induced hepatic steatosis by inhibiting cell apoptosis, lipid accumulation and oxide stress. Furthermore, the effect of DMY is likely associated with its role in the regulating of PPARγ, AMPK and AKT signaling pathways.
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Caifeng
C
Xie
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Zhen
Z
Chen
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Chengfu
C
Zhang
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Xin
X
Xu
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Jiangbo
J
Jin
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Weihua
W
Zhan
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.
Tianyu
T
Han
Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China. Electronic address: jianbinwang1@gmail.com.
Jianbin
J
Wang
D005234:Fatty Liver / Q000139:chemically induced / Q000473:pathology; D044948:Flavonols / Q000494:pharmacology*; D056945:Hep G2 Cells; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D050155:Lipogenesis / Q000187:drug effects*; D019301:Oleic Acid / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects*
D044948:Flavonols; D019301:Oleic Acid; C472036:dihydromyricetin
Apoptosis; Dihydromyricetin; Lipid accumulation; NAFLD; Oxidative stress